With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

UDENYCA® is a pegfilgrastim biosimilar used to reduce the chance of infection in patients with some tumors. Coherus BioSciences, headquartered in Redwood (NYSE:RWT) City, California, is known for its ...

UDENYCA® is a pegfilgrastim biosimilar used to reduce the chance of infection in patients with some tumors. Coherus BioSciences, headquartered in Redwood (NYSE:RWT) City, California, is known for ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...